share_log

Cantor Fitzgerald Maintains Overweight on Mesoblast, Lowers Price Target to $17

Cantor Fitzgerald Maintains Overweight on Mesoblast, Lowers Price Target to $17

坎托·菲茨杰拉德维持对Mesoblast的增持,将目标股价下调至17美元
Benzinga ·  2023/08/31 09:19

Cantor Fitzgerald analyst Louise Chen maintains Mesoblast (NASDAQ:MESO) with a Overweight and lowers the price target from $23 to $17.

Cantor Fitzgerald分析师Louise Chen维持中胚层(纳斯达克:MESO)增持,并将目标价从23美元下调至17美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发